Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

“…Full-dose FP was used most frequently, followed by low-dose FP. Various chemotherapy regimens of full-dose FP were included: (1) two cycles of cisplatin 70-80 mg/m 2 (day 1) and 5-FU 700-800 mg/m 2 /day administered as continuous intravenous infusion (IV) (days 1-4 or 1-5) [18][19][20], (2) two cycles of cisplatin 40 mg/m 2 (days 1 and 8) and 5-FU 400 mg/m 2 /day as continuous IV (days 1-5 and 8-12) [6,10], and (3) two or three cycles of cisplatin 60 mg/m 2 (day 1) and 5-FU 400 mg/m 2 /day as continuous IV (days 1-4) [9,21]. Low-dose FP included the following regimens: (1) two cycles of cisplatin 7 mg/m 2 (days 1-5 and 8-12) and 5-FU 250 mg/m 2 /day as continuous IV (days 1-14) [5,18,19], and (2) six weekly cycles of cisplatin 3-5 mg/m 2 (days 1-5) and 5-FU 180-250 mg/m 2 as continuous IV (days 1-5 or 1-7) [19,20,22].…”

“…The highest 5-year overall survival rate of 52% was achieved at Tenri Hospital. At the hospital, definitive CRT was performed for responders to neoadjuvant CRT of 44 Gy/40 fractions, and surgery was performed for non-responders [9,21]. This patient selection approach may be linked to the excellent survival rate.…”

Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer

“…Recently, the efficacy of CRT for SEC has been studied. Yamada et al [24] reported that the 5-year OS of CRT for stage I esophageal cancer was 66.4%. Kato et al reported the outcome of a phase II trial of CRT in patients with stage I esophageal cancer.…”

A suspected [18F]fluorodeoxyglucose positron emission tomography-negative metastatic lymph node successfully diagnosed by laparoscopic staging in esophageal cancer: Report of two cases

“…In case 1, the patient could have avoided an unnecessary thoracotomy had she demonstrated distant lymph node metastasis. Meanwhile, for clinical Stage I (T1N0M0) cancer patients, based on the report that the survival rate of defi nitive CRT was equivalent to that of surgery, 15 instead of surgery they have the option to receive defi nitive CRT that preserves the organ. In case 2, because the patient had a suspected node and despite wishing to preserve the esophagus, we fi nally selected a more curative strategy for him that entailed the use of our staging procedure.…”